| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5729705 | European Urology Focus | 2016 | 8 Pages |
Abstract
Fatigue is a well-known effect of antiangiogenic therapies (AATs) of cancer. The study performed in patients with treated metastatic renal cancer shows a decline of cognitive functions induced by AATs, such as information-processing speed or working memory, in a third of patients, independently of fatigue. Patients on AATs should be informed of these possible adverse effects.
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Florence Joly, Natacha Heutte, Brigitte Duclos, Sabine Noal, Isabelle Léger-Hardy, Sarah Dauchy, Nadine Longato, Laurence Desrues, Nadine Houede, Marie Lange, Emmanuel Sevin, Chantal Rieux, Bénédicte Clarisse, Hélène Castel, Bernard Escudier,